Should We Transplant Indolent Lymphoma?
- 1 September 2005
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (25) , 6263-6264
- https://doi.org/10.1200/jco.2005.01.5131
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphomaBlood, 2005
- 131I-Tositumomab Therapy as Initial Treatment for Follicular LymphomaNew England Journal of Medicine, 2005
- Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After RituximabJournal of Clinical Oncology, 2005
- Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular LymphomaJournal of Clinical Oncology, 2005
- Moderate Increase of Secondary Hematologic Malignancies After Myeloablative Radiochemotherapy and Autologous Stem-Cell Transplantation in Patients With Indolent Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study GroupJournal of Clinical Oncology, 2004
- Follicular Lymphoma International Prognostic IndexBlood, 2004
- High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From the Randomized European CUP TrialJournal of Clinical Oncology, 2003
- Secondary Acute Myelogenous Leukemia with MLL Gene Rearrangement Following Radioimmunotherapy (RAIT) for Non-Hodgkin's LymphomaLeukemia & Lymphoma, 2002
- High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trialBlood, 2001
- Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experienceBlood, 2000